CTOs on the Move

Rejuvenate Bio

www.rejuvenatebio.com

 
Rejuvenate Bio is developing novel therapies to treat aging and age-related diseases through innovative targeted gene therapies, is developing treatments to reverse aging and address multiple age-related diseases.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Rejuvenate Bio raised $14.5M on 04/27/2021

Similar Companies

Mineralys Therapeutics

At Mineralys Therapeutics we aim to redefine hypertension diagnosis, management and treatment. We are driven to break the “trial and failure” approach to hypertension management and bring a personalized approach to the management of hypertension.

BioStar Systems

BioStar Systems is a Kansas City, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bedrocan

Bedrocan is an experienced producer of pharmaceutical-grade medicinal cannabis with over 13 years growing expertise in global markets. We provide patients and healthcare professionals with safe, effective and consistent medicine for the appropriate management of diagnosed health conditions. Our strains of pharmaceutical-grade cannabis are used by thousands of patients in seven countries, including Canada. We provide three fully standardized products, and as a result, our standardized strains are the choice for researchers and academics who study the medical effects of cannabis.

Hepion Pharmaceuticals

Hepion Pharmaceuticals is a biopharmaceutical company focused on the development of pleiotropic drug therapy for treatment of chronic liver disease. T

Arrowhead Research

Arrowhead Research Corporation is a biopharmaceutical company developing targeted RNAi therapeutics. The company is leveraging its proprietary Dynamic Polyconjugate delivery platform to develop targeted drugs based on the RNA interference mechanism that efficiently silences disease-causing genes. Arrowhead`s pipeline includes ARC-520 for chronic hepatitis B virus, ARC-AAT for liver disease associated with Alpha-1 antitrypsin deficiency, and partner-based programs in obesity and oncology.